Ocugen (OCGN) Capital Expenditures Growth (1y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 227.76% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 0.57% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 143.40% |
| 10 | Ocugen | 452.01 Mn | 452.01 Mn | - | -62.50% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -62.50% |
| Dec 31, 2025 | 1,176.92% |
| Sep 30, 2025 | -107.89% |
| Jun 30, 2025 | -98.28% |
| Mar 31, 2025 | -95.69% |
| Dec 31, 2024 | -99.52% |
| Sep 30, 2024 | -84.93% |
| Jun 30, 2024 | -10.19% |
| Mar 31, 2024 | -76.99% |
| Dec 31, 2023 | 278.84% |
| Sep 30, 2023 | 73.27% |
| Jun 30, 2023 | 2,414.17% |
| Mar 31, 2023 | 163.83% |
| Dec 31, 2022 | -892.71% |
| Sep 30, 2022 | 770.85% |
| Jun 30, 2022 | -145.63% |
| Mar 31, 2022 | 134.10% |
| Dec 31, 2021 | -23.51% |
| Sep 30, 2021 | 298.21% |
| Dec 31, 2020 | 12,243.20% |
| Jun 30, 2019 | 83.31% |
| Mar 31, 2019 | -98.83% |
| Sep 30, 2018 | -1,462.43% |
| Jun 30, 2018 | -234.21% |
| Mar 31, 2018 | 2,345.95% |
| Dec 31, 2017 | 4,700.00% |
| Sep 30, 2017 | 1,800.00% |
| Jun 30, 2017 | -86.52% |
| Mar 31, 2017 | 15.63% |
| Dec 31, 2016 | -97.71% |
| Sep 30, 2016 | -99.40% |
| Jun 30, 2016 | -30.37% |
| Mar 31, 2016 | -96.50% |
| Dec 31, 2015 | -92.49% |
| Sep 30, 2015 | -64.02% |
| Jun 30, 2015 | 454.79% |
| Mar 31, 2015 | 662.50% |